Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

Conditions

• Scalp Psoriasis

Eligibility Criteria

Sex

ALL

Age

12 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Roflumilast Foam 0.3% — DRUG
  Roflumilast foam 0.3%
• Vehicle Foam — DRUG
  Vehicle foam matched to roflumilast 0.3% foam.

Study Details

This was a parallel group, double blind, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-154) 0.3% foam vs vehicle foam applied once daily (qd) for 8 weeks by participants with plaque psoriasis of the scalp and body.

Key Dates

Start date

Aug 24, 2021

Status verified

Jul 2025

Primary completion

Jun 3, 2022

Completion

Jun 3, 2022

Study Design

Enrollment

432 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: Roflumilast Foam 0.3%
  Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% once daily (qd) for 8 weeks.
• Placebo Comparator: Vehicle Foam
  Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.

Primary Outcome Measure

Achievement of Scalp Investigator Global Assessment (S-IGA) "Success" at Week 8 [ Time Frame: Week 8 ]

Locations (36)

Find similar trials in Scottsdale, AZ